Sai Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma CDMO
- May 15, 2026
- Posted by: Kunal Singla
- Category: News
Sai Life Sciences Q4 FY26 results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT rose 18.09% YoY to Rs 104.24 crore on revenue of Rs 602.14 crore (+3.91% YoY). FY26 annual PAT Rs 348.91 crore (+105% YoY); FY26 revenue Rs 2,192.49 crore (+29.38%). CRDMO business momentum sustained with CDMO at 65% and CRO at 35% of revenue mix. 9M FY26 PAT was Rs 245 crore (+199% YoY). Capital expenditure of Rs 633 crore in FY26 to expand manufacturing and R&D capacity. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Sai Life Sciences Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| PAT (Net Profit) | Rs 104.24 crore | up 18.09% YoY from Rs 88.27 crore in Q4 FY25 |
| Revenue from Operations | Rs 602.14 crore | Q4 FY26 |
| Ticker | SAILIFE | Sector: Pharma CDMO |
Screen the best stocks on the Univest Screener.
Sai Life Sciences Performance Analysis
The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company is an innovator-focused CRDMO (Contract Research, Development and Manufacturing Organization) with revenue estimation of Rs 370-40 Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.
The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.
Sai Life Sciences FY27 Outlook
Post Sai Life Sciences, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharma CDMO space. The Sai Life Sciences results demonstrate the company’s execution capabilities. Track Sai Life Sciences updates on the Univest Screener for analyst views and FY27 earnings estimates.
Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.
Frequently Asked Questions on Sai Life Sciences Q4 FY26 Results
What is Sai Life Sciences Q4 FY26 PAT?
Ans. Sai Life Sciences Q4 FY26 PAT of Rs 104.24 crore (results declared May 14, 2026). Q4 FY26 PAT rose 18.09% YoY to Rs 104.24 crore on revenue of Rs 602.14 crore (+3.91% YoY). FY26 annual PAT Rs 348.91 crore (+105% YoY); FY26 revenue R.
When did Sai Life Sciences announce Q4 FY26 results?
Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.
What is the FY27 outlook for Sai Life Sciences?
Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharma CDMO sector. Track live updates on the Univest Screener.
Where can I track Sai Life Sciences Q4 FY26 live data?
Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
